Modus Therapeutics Holding AB (publ), a biotechnology company, develops a treatment for sepsis and septic shock in Sweden. It develops Sevuparin, a lipopolysaccharide to treat patients with sepsis, septic shock, and severe malaria conditions, which is under Phase Ib clinical study. The company was founded in 2011 and is headquartered in Stockholm, Sweden.